• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Merkel cell carcinoma with synchronous but spatially distinct squamous cell carcinoma of the head: Case report of differing PRAME expression and response to checkpoint inhibitor therapy.

作者信息

Abbott Claire B, Nanda Sonali, Phan Minh, Asadbeigi Sepideh, McBride Jeffrey

机构信息

OU Health Sciences Center, College of Medicine, Oklahoma City, Oklahoma.

Department of Dermatology, OU Health Sciences Center, Oklahoma City, Oklahoma.

出版信息

JAAD Case Rep. 2025 Jul 17;64:63-66. doi: 10.1016/j.jdcr.2025.05.051. eCollection 2025 Oct.

DOI:10.1016/j.jdcr.2025.05.051
PMID:40933628
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12418887/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12418887/6cc899615767/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12418887/50428176ce68/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12418887/5cf7f33d7e04/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12418887/6cc899615767/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12418887/50428176ce68/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12418887/5cf7f33d7e04/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12418887/6cc899615767/gr3.jpg

相似文献

1
Merkel cell carcinoma with synchronous but spatially distinct squamous cell carcinoma of the head: Case report of differing PRAME expression and response to checkpoint inhibitor therapy.Merkel 细胞癌合并头面部同步但位置不同的鳞状细胞癌：PRAME 表达差异及对检查点抑制剂治疗反应的病例报告
JAAD Case Rep. 2025 Jul 17;64:63-66. doi: 10.1016/j.jdcr.2025.05.051. eCollection 2025 Oct.
2
Administration of a Single Dose of Pembrolizumab, Docetaxel, and Cisplatin Leads to Complete Disappearance of a Locally Advanced Hypopharyngeal Squamous Cell Carcinoma: A Case Report.单剂量帕博利珠单抗、多西他赛和顺铂联合给药导致局部晚期下咽鳞状细胞癌完全消失：一例报告
Case Rep Oncol. 2025 Jun 25;18(1):1012-1020. doi: 10.1159/000547116. eCollection 2025 Jan-Dec.
3
Spatially organized inflammatory myeloid-CD8 T cell aggregates linked to Merkel-cell Polyomavirus driven Reorganization of the Tumor Microenvironment.与默克尔细胞多瘤病毒驱动的肿瘤微环境重塑相关的空间组织化炎性髓样细胞-CD8 T细胞聚集体
bioRxiv. 2025 Jun 6:2025.06.06.657162. doi: 10.1101/2025.06.06.657162.
4
Immune checkpoint inhibitors combined with targeted therapy for long-term survival in advanced pulmonary squamous cell carcinoma after first-line failure: A case report and literature review.免疫检查点抑制剂联合靶向治疗用于一线治疗失败后晚期肺鳞状细胞癌的长期生存：一例报告及文献综述
Medicine (Baltimore). 2025 Jun 20;104(25):e42724. doi: 10.1097/MD.0000000000042724.
5
Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy.意大利含西妥昔单抗方案治疗头颈部鳞状细胞癌的成本效益
Future Oncol. 2025 Jun;21(14):1779-1786. doi: 10.1080/14796694.2025.2503667. Epub 2025 May 18.
6
Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinoma.免疫相关不良反应对头颈部鳞状细胞癌患者生存的影响。
Immunotherapy. 2024;16(16-17):1069-1078. doi: 10.1080/1750743X.2024.2409617. Epub 2024 Oct 11.
7
Multiplexed immune profiling and 3D co-culture assays to assess the individual checkpoint therapy response in head and neck squamous cell carcinoma.用于评估头颈部鳞状细胞癌个体检查点治疗反应的多重免疫分析和3D共培养试验
Front Oncol. 2025 Aug 8;15:1622008. doi: 10.3389/fonc.2025.1622008. eCollection 2025.
8
Complete response with pembrolizumab in recurrent squamous cell carcinoma of the oral tongue: A case report.帕博利珠单抗治疗复发性口腔舌鳞癌完全缓解：一例报告。
Oral Oncol. 2023 Dec;147:106597. doi: 10.1016/j.oraloncology.2023.106597. Epub 2023 Oct 17.
9
STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.STELLAR-305：zan zalintinib联合帕博利珠单抗对比单独使用帕博利珠单抗治疗头颈部鳞状细胞癌患者的II/III期研究。
Future Oncol. 2025 May;21(11):1349-1356. doi: 10.1080/14796694.2025.2485015. Epub 2025 Apr 18.
10
Coexistence of head and face Merkel cell and squamous cell carcinomas in the elderly population - a case report and literature review.老年人群头面部默克尔细胞癌与鳞状细胞癌并存——病例报告及文献综述
Pol J Pathol. 2025;76(1):59-63. doi: 10.5114/pjp.2025.149383.

本文引用的文献

1
PRAME Expression in Merkel Cell Carcinoma.PRAME 在 Merkel 细胞癌中的表达。
Am J Surg Pathol. 2024 Oct 1;48(10):1270-1276. doi: 10.1097/PAS.0000000000002288. Epub 2024 Jul 12.
2
PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.PRAME 更新：在皮肤癌中的诊断、预后和治疗作用。
Int J Mol Sci. 2024 Jan 27;25(3):1582. doi: 10.3390/ijms25031582.
3
Differential gene expression and network analysis in head and neck squamous cell carcinoma.头颈部鳞状细胞癌中的差异基因表达和网络分析。
Mol Cell Biochem. 2022 May;477(5):1361-1370. doi: 10.1007/s11010-022-04379-3. Epub 2022 Feb 10.
4
Preferentially expressed antigen in melanoma expression in nonmelanoma skin cancers and melanocytes in surrounding skin.黑色素瘤中优先表达的抗原在非黑色素瘤皮肤癌及周围皮肤的黑色素细胞中的表达。
J Cutan Pathol. 2021 Sep;48(9):1150-1155. doi: 10.1111/cup.14012. Epub 2021 Mar 28.
5
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.FDA 加速批准帕博利珠单抗用于治疗复发性局部晚期或转移性 Merkel 细胞癌。
Oncologist. 2020 Jul;25(7):e1077-e1082. doi: 10.1634/theoncologist.2020-0184. Epub 2020 Apr 28.
6
The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer.癌睾丸抗原 PRAME 在人类癌症发生和免疫治疗中的作用。
Cell Prolif. 2020 Mar;53(3):e12770. doi: 10.1111/cpr.12770. Epub 2020 Feb 5.
7
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗在含铂化疗期间或之后出现疾病进展的复发性或转移性头颈部鳞状细胞癌。
Oncologist. 2017 Jul;22(7):873-878. doi: 10.1634/theoncologist.2016-0496. Epub 2017 May 22.
8
Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins.黑色素瘤中优先表达的抗原（PRAME）及富含亮氨酸重复序列蛋白的PRAME家族
Curr Cancer Drug Targets. 2016;16(5):400-14. doi: 10.2174/1568009616666151222151818.